Sobi (Swedish Orphan Biovitrum AB)

Trending Articles

  1. NHS, MHRA and Medicines UK launch Project Revive to tackle medicine shortages NHS England, the MHRA and Medicines UK have launched Project Revive, a collaborative pilot designed to address critical medicines shortages by fast-tracking dormant...
  2. Isopod Rapid Cleanrooms: the ideal elite controlled environment pod solution for Life Sciences and Engineering start-ups The Guardtech Group’s quick-assembly cleanroom pods combine superior performance, build quality and cost-effectiveness to give new applications the perfect platform to get...
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Delivering precision: why advanced therapies are redefining pharmaceutical logistics As advanced therapies narrow tolerances and personalise care, pharmaceutical logistics is being redefined as a precision-driven extension of treatment delivery, writes Michael...
  4. Nose-to-brain delivery outperforms systemic BBB technologies according to MetP Pharma The pioneering company has published preclinical data that strongly supports the advantages of its proprietary nose-to-brain drug delivery technology compared with systemic...
  5. AstraZeneca strengthens weight management pipeline with CSPC Pharmaceuticals collaboration The pair have signed a strategic collaboration covering eight obesity and type 2 diabetes programmes, including a clinical-ready GLP-1/GIP asset, AI-driven peptide discovery...

Upcoming event

High Shear = Mixing Success

19 February 2026 | Virtual See all

Related Content

Ingredients

Therapeutic: loncastuximab tesirine for diffuse large B-cell lymphoma

Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of blood cancer. Up to 40% of patients will require further lines of treatment as their disease relapses or becomes refractory to first line treatment
Ingredients

Therapeutic for paroxysmal nocturnal haemoglobinuria: pegcetacoplan

Paroxysmal nocturnal haemoglobinuria (PNH) is a rare and chronic blood disorder in which red blood cells are destroyed via extravascular and intravascular haemolysis
Finance

Sobi to acquire Synagis US rights from AstraZeneca

Synagis, the only approved respiratory syncytial virus prophylaxis for high-risk infants, complements Sobi’s expertise in paediatrics and immunology
Recruitment

Fredrik Wetterlundh joins Sobi
Pharmaceutical

Sobi establishes new leadership structure and appoints Torbjorn Hallberg as General Counsel
Pharmaceutical

Norbert Oppitz joins Sobi as new Senior VP, Specialty Care
Finance

Sobi enters into new distribution agreement with Valeant for Ammonul

The company has entered into a three-year agreement with Valeant Pharmaceuticals Ireland for the distribution in Europe, the Middle East and North Africa
Subscribe now